Journal Articles
Liquid biopsy for cancer management
-
Dr Tomasz Powrózek
,
Department of Human Physiology, Medical University in Lublin
,
Poland
One of the major advantage for analysis of circulating nucleic acids as cancer biomarkers is their remarkable stability in body fluids and significantly altered expression under the cancer conditions. They are both released to blood circulation from cancerous tissues (directly or within the exosomes) or from host tissues affected by tumor occurrence. Monitoring of circulating biomarkers, especially in blood circulation (plasma or serum) is more convenient and safer for patient than series of tissue biopsy. Liquid biosy allows to capture the entire heterogeneity of the tumor (primary/metastatic/recurrent) with minimally invasive manner. Liquid biopsy offers clinical applicability for cancer detection, prediction and prognosis. The aim of the special issue is summarizing the utility of circulating biomarkers (expression of ncRNAs, DNA methylation) with the use of liquid biopsy for cancer management.
Submission deadline:
07/01/2025
